Results 231 to 240 of about 1,591,231 (284)
Some of the next articles are maybe not open access.
Health Affairs, 2021
Researchers and policy makers in the US are exploring the implementation of health technology assessment and value-based pricing to negotiate drug prices and limit spending.
L. Rand, A. Kesselheim
semanticscholar +1 more source
Researchers and policy makers in the US are exploring the implementation of health technology assessment and value-based pricing to negotiate drug prices and limit spending.
L. Rand, A. Kesselheim
semanticscholar +1 more source
Practical Neurology, 2008
Many health systems now use cost-effectiveness analysis to decide which interventions and programmes to fund. A key issue for such decision making is how to measure health outcomes from interventions to reflect changes in both health-related quality of life and life expectancy.
Yolanda, Bravo Vergel, Mark, Sculpher
openaire +3 more sources
Many health systems now use cost-effectiveness analysis to decide which interventions and programmes to fund. A key issue for such decision making is how to measure health outcomes from interventions to reflect changes in both health-related quality of life and life expectancy.
Yolanda, Bravo Vergel, Mark, Sculpher
openaire +3 more sources
Quality-Adjusted Life Years (QALYs)
Encyclopedia of Behavioral Medicine, 2013J. Rick Turner +6 more
openaire +2 more sources
Multiple Sclerosis, 2020
Objectives: To quantify life expectancy (LE), quality-adjusted life years (QALYs) and total lifetime societal costs for a hypothetical cohort of Australians with multiple sclerosis (MS).
A. Palmer +5 more
semanticscholar +1 more source
Objectives: To quantify life expectancy (LE), quality-adjusted life years (QALYs) and total lifetime societal costs for a hypothetical cohort of Australians with multiple sclerosis (MS).
A. Palmer +5 more
semanticscholar +1 more source
Journal of Clinical Oncology, 2019
207 Background: In patients previously treated for aHCC, cabozantinib (cabo) led to longer overall survival and progression-free survival vs placebo (pbo) in the randomized, phase 3 CELESTIAL trial (NCT01908426; N = 707).
G. Abou-Alfa +11 more
semanticscholar +1 more source
207 Background: In patients previously treated for aHCC, cabozantinib (cabo) led to longer overall survival and progression-free survival vs placebo (pbo) in the randomized, phase 3 CELESTIAL trial (NCT01908426; N = 707).
G. Abou-Alfa +11 more
semanticscholar +1 more source
Medical Care, 2018
Background: Although the life expectancy for the US population has increased, a high proportion of this population has lived with ≥1 chronic conditions.
Haomiao Jia +7 more
semanticscholar +1 more source
Background: Although the life expectancy for the US population has increased, a high proportion of this population has lived with ≥1 chronic conditions.
Haomiao Jia +7 more
semanticscholar +1 more source
Journal of Arthroplasty, 2018
BACKGROUND Hip osteoarthritis is a leading cause of functional decline and disability in the elderly. Although patients older than 80 years could significantly benefit from an elective total hip arthroplasty (THA), they pose a significant challenge to ...
D. Dimitriou +4 more
semanticscholar +1 more source
BACKGROUND Hip osteoarthritis is a leading cause of functional decline and disability in the elderly. Although patients older than 80 years could significantly benefit from an elective total hip arthroplasty (THA), they pose a significant challenge to ...
D. Dimitriou +4 more
semanticscholar +1 more source
Abstract The concept of quality-adjusted life years (QALY) is explained, with the approaches to measuring and problems with QALYs highlighted.
Phil Ambery +2 more
openaire +2 more sources
Phil Ambery +2 more
openaire +2 more sources